.png)
SummaryA European drug pricing database is a dataset that brings medicine prices from multiple European countries into one comparable structure, and it has to be assembled country by country because no pan-European price register exists. Every country runs its own product registry, its own article identifier, its own reimbursement regime and its own update cadence, so cross-border comparison is a mapping problem before it is a data problem.
That is the honest starting point, and it is the one most sources skip. There is no European equivalent of a single national article master. The European Medicines Agency authorises medicines centrally for the EU, but pricing and reimbursement remain national competences. A centrally authorised product can carry a different price, a different reimbursement status, a different pack range and a different brand name in every single member state.
This article explains why European price comparison is structurally hard, how external reference pricing quietly links national prices to each other, what the German, Austrian and Swiss systems actually look like, why parallel trade exists as a direct consequence, and what a European price dataset needs to contain before it is usable.
Four structural facts explain it.
The practical consequence: any European price comparison is the output of a mapping exercise, and the quality of the comparison is determined by the quality of that mapping rather than by the prices themselves.
External reference pricing, also called international reference pricing, is the practice of using the price of a medicine in one or several other countries as a benchmark for setting or negotiating its price domestically. It is the mechanism that makes cross-border price data commercially consequential rather than merely interesting.
It is close to universal in Europe. A review of 31 European countries published in the Journal of Market Access and Health Policy in 2015 found that all of the countries studied applied external reference pricing except the United Kingdom and Sweden. The same review found wide methodological divergence: basket sizes ranged from a single reference country to 31, and countries variously used the average price, the lowest price in the basket, or other calculation rules.
The World Health Organization's guideline on country pharmaceutical pricing policies discusses the use of external reference pricing as a policy instrument, including its limitations, among them the fact that published list prices in reference countries may not reflect the confidential net prices actually paid.
Three implications follow for anyone working with European price data.
"The regulator requires that there is a comparison with other prices throughout Europe." (Regulatory Affairs Manager at a medical technology manufacturer, adjacent segment)
Germany allows a manufacturer to set the launch price freely, then reassesses it. For a new active substance, the Federal Joint Committee conducts an early benefit assessment under section 35a SGB V, and a reimbursement amount (Erstattungsbetrag) is subsequently negotiated with the statutory health insurance side. Where no added benefit is established, a product can be moved into the reference price system.
Alongside that sits the Festbetrag, a statutory reimbursement ceiling applied to groups of comparable products. A product may be priced above its Festbetrag, with the difference falling to the patient, so the list price and the reimbursed amount are two separate numbers.
Below both sits the rebate contract layer, where individual manufacturers agree confidential discounts with individual sickness funds. For a European comparison this matters enormously: Germany's published list price is a real, referenceable, regulated number, and it is also not what the payer pays.
Austria organises reimbursement through the Erstattungskodex (EKO), in force since 1 January 2005, which lists the medicines paid for by the social insurance carriers together with their prices. Its defining feature is the colour-coded box system, described in the social insurance system's information tool on the Erstattungskodex.
| Box | Meaning |
|---|---|
| Red box | Products for which an application for inclusion has been submitted and is under assessment |
| Yellow box | Products with an additional therapeutic benefit that are not in the green box for medical or economic reasons, subdivided into RE1 and RE2 |
| Green box | Products reimbursed without individual prior approval, subject to any stated restrictions on indication, age group or prescriber |
Separately from reimbursement, the Warenverzeichnis published by the Austrian pharmacists' publishing house is the reference listing of marketed articles, carrying Austrian Pharmazentralnummern, pack sizes, price information and storage requirements. For cross-border work the two are complementary: the Warenverzeichnis tells you what exists and at what price, the Erstattungskodex tells you how it is reimbursed.
Note the trap for German-speaking teams. Austria and Germany share a language and even share the term Pharmazentralnummer, but the number spaces are entirely separate. A German PZN does not resolve against an Austrian article.
Switzerland is not an EU member state, which means EU pharmaceutical law does not apply and Swiss data has to be sourced separately. Reimbursed medicines are listed on the Spezialitätenliste (SL) maintained by the Federal Office of Public Health (BAG), and the listed prices are maximum prices composed of an ex-factory price, a distribution margin and VAT.
What makes Switzerland especially instructive is that its pricing method is explicitly and openly a reference-pricing method. According to the BAG's information on Swiss medicine prices, a product's price is determined using two instruments in combination:
Switzerland then also re-examines listed products periodically rather than fixing the price once. On the article side, Switzerland uses the seven-digit Pharmacode as its primary article key, complemented by GTIN.
The point for a European dataset: a Swiss price is not an isolated data point. It is partly a function of German, Austrian and French prices, which is exactly why a Swiss-based team monitoring only Swiss data is working with an incomplete picture of its own market.
Beyond DACH, the systems diverge along a small number of recurring axes rather than being infinitely varied. Understanding the axes is more useful than memorising individual regimes, and it protects you from assuming that a field which exists in one country exists everywhere.
| Axis | What varies | Why it matters for a dataset |
|---|---|---|
| Price setting | Free pricing at launch with later assessment, versus prior approval before market entry | Determines whether an early observed price is provisional or final |
| Reference method | Average of basket, lowest in basket, or other formula, with basket sizes from one country to dozens | Determines which other countries' prices are load-bearing for a given market |
| Reimbursement instrument | Positive list, negative list, reference price groups, therapeutic categories | Determines what "reimbursed" even means as a field value |
| Confidential discounts | Managed entry agreements and rebates that sit below the published price | Determines the gap between list price and net price |
| Price level in the chain | Ex-factory, wholesale, pharmacy retail, with or without VAT | The most common source of false comparisons |
| Publication cadence | Monthly, twice-monthly, or rolling decision-based updates | Determines whether two countries in one extract are time-aligned |
The fifth row deserves emphasis because it produces more wrong answers than any other. VAT on medicines varies substantially across Europe, and distribution margins are regulated differently. Comparing a German pharmacy retail price against a Swiss ex-factory price is not a price comparison, it is a category error. Any serious European dataset must state, per country and per field, which point in the distribution chain the number refers to and whether tax is included.
Because prices for the same medicine differ across the single market, and because goods move freely within it, an entire trade exists to exploit the gap. Parallel trade is the purchase of an authorised medicine in a lower-priced member state and its resale in a higher-priced one, outside the manufacturer's own distribution channel.
It is lawful. The European Commission's position on parallel imports of proprietary medicinal products treats them as a legitimate form of trade within the internal market, grounded in the free movement of goods, subject to safeguards for public health and for industrial and commercial property.
Three data consequences follow. First, parallel-imported products appear in national article registries as separate articles, with their own identifiers, their own distributor and typically their own price, so a national article count includes them. Second, they compress the price differential they exploit, which means the differential itself is a moving quantity. Third, for anyone doing supply or shortage analysis, parallel imports are a real alternative source and appear in the data as such.
If you are specifying or evaluating one, these are the criteria that decide whether it will hold up.
A dataset that meets the first two of these is already unusual. One that meets all eight is what makes cross-border pricing work repeatable rather than a quarterly research project.
DACON Datenbank Consulting GmbH has maintained pharmaceutical reference data since 1989. pharmazie.com consolidates 25+ databases into one platform covering more than 50,000 German products and more than 120,000 international products across 50+ countries, including Austrian data from the Austria Codex and Swiss data alongside the German article master. It bundles all three data layers in one platform, clinical (interaction and safety data), commercial (prices and reimbursement) and logistical (article identifiers and supply-shortage data), plus international product data across 50+ countries in 25+ databases, whereas most individual sources cover only one of these areas. Price coverage itself spans DACH today, with further European markets added over the coming months, while product data already reaches 50+ countries.
The differentiator for cross-border work is specific rather than general: DACH depth plus international breadth in a single query surface, so that a question such as "what does this substance cost, in which pack sizes, under which reimbursement status, in Germany, Austria and Switzerland at the same reference date" is one search rather than three national subscriptions and a reconciliation spreadsheet. The same data is available through a REST interface for teams that need it inside their own systems. For cross-border pricing questions across DACH, and cross-layer questions against product data from 50+ countries, that consolidation is the reason customers use it.
Access to pharmazie.com starts from EUR 135/month, and pricing is published openly at go.pharmazie.com/preise, whereas most other providers in this space communicate no public list price.
If you are moving from understanding the problem to choosing a source, two further reads are directly relevant.
This content is intended for healthcare professionals and does not constitute medical advice. Last reviewed: July 2026.
